Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02589366 · ClinicalTrials.gov registry record · Phase 1
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02589366: Clinical Trial Phase 1 study, sponsored by University of California, San Diego.
NCT02589366 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02589366, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against infection and cancer). The purpose of this study is to compare the safety and ability of Lymphoseek and a Vital Blue Dye (tracing agent) to find lymph nodes that may carry cancer from the tumor through the lymphatic system. Lymphoseek will be injected into the tumor on the day before surgery to remove lymph nodes. Vital Blue Dye will be administered during surgery to trace the cancer as well. The surgeon will remove the lymph nodes as part of routine surgery and will keep track of which lymph nodes are identified by Lymphoseek and Vital Blue Dye. These nodes will be sent to another doctor to view them under a microscope and see if the nodes contain cancer cells. The hypothesis is that Lymphoseek can be used safely and will be at least as effective as blue dye in identifying the lymph nodes that may have cancer cells.
Primary Outcome
Adverse events experienced by the participants and radiation absorbed dose of injected Lymphoseek.
Interventions
- DRUG Lymphoseek plus Vital Blue Dye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Why NCT02589366 stopped before completion
NCT02589366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Lymphoseek plus Vital Blue Dye is the first listed.
NCT02589366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02589366 about?
NCT02589366 is a clinical study titled "Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium". Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against in...
What is the current status of trial NCT02589366?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02589366?
The interventions under investigation include: Lymphoseek plus Vital Blue Dye (DRUG).
Who is sponsoring clinical trial NCT02589366?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02589366's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia